Weekly Recap: Yartemlea U.S. forecast raised and Omeros hits 52-week high
Omeros Corporation (NASDAQ:OMER) shares jumped to a 52-week high near $20.68 after analysts raised peak U.S. sales for its drug Yartemlea to about $400M, forecasting a 35—40% U.S. market share while expecting minimal European contribution.Previous Week RecapThis is an AI-generated summary and may c…